Infinity Pharmaceuticals revealed in its second quarter 2012 financial report that it cut 20% of its workforce - 40 employees at the company's Cambridge, Massachusetts headquarters - after shutting down its Hedgehog pathway programme and renegotiating its partnership with Mundipharma International.
Infinity Pharmaceuticals revealed in its second quarter 2012 financial report that it cut 20% of its workforce - 40 employees at the company's Cambridge, Massachusetts headquarters - after shutting down its Hedgehog pathway programme and renegotiating its partnership with Mundipharma International.
Infinity had $104.6 million in cash and investments as of 30 June compared to a $104.9 million cash balance on 31 March. But despite a stable cash position, with $28.5...
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.
Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.
